Inhaled exosome therapy lowers respiratory failure in phase 2b ARDS trial
Nano24’s EXO-CD24 moved from concept to clinic with a result that carries immediate weight in acute respiratory distress syndrome. In a phase 2b study of 90 patients, the inhaled therapy reduced respiratory failure by Day 7 and was associated with lower all-cause mortality through 28 days and six months.
The signal arrived in a disease where bedside management still depends heavily on supportive care. ARDS drives diffuse lung inflammation, impaired oxygen exchange, and a cascade that can end in multi-organ failure. Even with modern critical care, clinicians still lack an approved drug that directly targets the syndrome itself, so a treatment that can blunt the inflammatory injury without suppressing host defense is clinically attractive.
Patients in the active arm received EXO-CD24 at 1010 particles per dose, administered twice daily for five days. By Day 7, 85% of treated patients had avoided respiratory failure, compared with 33.3% in the placebo group. That endpoint sits at the center of the study’s clinical value: in ARDS, delaying or preventing respiratory failure can reduce the need for invasive ventilation and may lower the cascade of complications that follows intensive respiratory support.
Mortality and length of stay moved in the same direction
The mortality findings were harder to ignore. All-cause death over 28 days occurred in 6.7% of patients who received EXO-CD24, compared with 30% in the placebo arm. At six months, mortality stood at 13.3% in the treatment cohort and 43.3% in the placebo cohort. Those figures extend the short-term respiratory endpoint into a broader clinical frame, suggesting that a treatment effect confined to transient oxygenation improvement did not explain the entire pattern.
Hospital utilization also favored the investigational arm. Mean hospital stay was 6.5 days during the 28-day observation window for the EXO-CD24 group, versus 14.4 days for placebo. Shorter hospitalization in ARDS can reflect less ventilatory support, fewer downstream organ complications, and earlier stabilization of the inflammatory injury in the lungs.
The study also reported no treatment-related serious adverse events. Fewer serious and non-serious adverse events occurred in the EXO-CD24 group than in the placebo group, and the therapy was described as well tolerated. In a population already at high risk for clinical deterioration, tolerability is not a side issue. A lung-directed anti-inflammatory therapy must do more than work on paper; it has to avoid worsening the infection-fighting capacity that patients with sepsis, pneumonia, or other triggers of ARDS still need.
Why the biology matters in ARDS
EXO-CD24 combines engineered exosomes with the immunomodulatory protein CD24. Exosomes are tiny membrane-bound vesicles that can be used as delivery vehicles, and their appeal in respiratory disease is straightforward: inhalation sends the therapeutic directly to the lungs, where the inflammatory process is unfolding. The goal is not broad immunosuppression. It is to control the damage-driven inflammation that can amplify lung injury while preserving the body’s ability to identify and clear pathogens.
That mechanism fits the core pathology of ARDS. The syndrome is not defined only by hypoxemia; it reflects an uncontrolled inflammatory response that disrupts the alveolar-capillary barrier, floods the lungs, and makes oxygen transfer progressively less efficient. A therapy aimed at that pathway has a plausible route to changing the clinical course if it can intervene early enough and with enough precision.
Matthew Baldwin, a pulmonary and critical care physician-scientist, described the Day 7 respiratory-failure result and the mortality findings as encouraging in a deadly condition. The clinical context explains why. In ARDS, even modest shifts in the trajectory of respiratory decline can change ICU needs, ventilatory intensity, and the chance of surviving the acute phase.
A first clinical proof point for Nano24’s platform
The study carries additional significance for Nano24 because it represents the first clinical proof-of-concept for the company’s engineered exosome platform. Founded in 2020 to advance research from Tel Aviv Sourasky Medical Center, the biotech is built around the idea that exosomes can be customized for targeted therapy in high-unmet-need diseases. Robert Langer, who heads the scientific board, framed exosomes as a promising drug-delivery foundation because their surface and cargo can be engineered to work together.
This result does not settle the field. A 90-patient phase 2b study can show a strong signal, but it cannot by itself define the size of benefit that will hold in a larger, more heterogeneous population. ARDS is a syndrome, not a single disease, and the trigger can range from sepsis to pneumonia and other severe insults. Response may vary depending on disease cause, timing of treatment, ventilatory strategy, and the intensity of concurrent critical care.
The next step is a larger global phase 3 study. That trial will need to determine whether the respiratory-failure benefit persists across broader clinical settings and whether the mortality difference remains durable when the therapy is tested in a more representative ARDS population. It will also need to clarify how early the drug must be given, which patients are most likely to benefit, and whether the inhaled exosome platform can reproduce the same safety profile at scale.
Nano24 is also exploring EXO-CD24 in other inflammatory diseases, but ARDS now stands as the clearest clinical benchmark for the platform. The central question for the next stage is not whether inflammation can be modulated in the lung; this study suggests it can. The more demanding question is whether that biologic control can be converted into consistent survival benefit in a disease where outcomes are often shaped by both the initial injury and the course of critical care that follows.